32
All treated patients (n = 77)
≥1% PD-L1 (n = 46)
≥50% PD-L1 (n = 13)
1-year OS rate: 76%
100
80
60
40
20
0
OS (%)
0
6
12
18
24
30
36
42
48
100
80
60
40
20
0
0
6
12
18
24
30
36
42
48
1-year OS rate: 87%
100
80
60
40
20
0
0
6
12
18
24
30
36
42
48
1-year OS rate: 100%
Nivo 3 Q2W +
ipi 1 Q6/12W
1-year OS rate: 73%
100
80
60
40
20
0
Months
OS (%)
0
6
12
18
24
30
36
42
48
100
80
60
40
20
0
Months
0
6
12
18
24
30
36
42
48
1-year OS rate: 69%
100
80
60
40
20
0
Months
0
6
12
18
24
30
36
42
48
1-year OS rate: 83%
All treated patients (n = 52)
≥1% PD-L1 (n = 32)
≥50% PD-L1 (n = 12)
Nivo 3 Q2W
Gettinger S, et al. WCLC 2016
Nivolumab plus Ipilimumab
